{"id":"clofarabine-ara-c","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea"},{"rate":"20-40%","effect":"Vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Diarrhea"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Clofarabine and ara-C are both antimetabolites that work by inhibiting DNA polymerase, which is necessary for DNA replication and cell division. This leads to cell death, particularly in rapidly dividing cancer cells.","oneSentence":"Clofarabine is a nucleoside analog that interferes with DNA synthesis, while ara-C is a cytosine analog that also interferes with DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:31:14.389Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia"},{"name":"Acute myeloid leukemia"}]},"trialDetails":[{"nctId":"NCT03117751","phase":"PHASE2, PHASE3","title":"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-03-29","conditions":"Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma","enrollment":790},{"nctId":"NCT02883049","phase":"PHASE3","title":"Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-02-29","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia","enrollment":5949},{"nctId":"NCT07156435","phase":"PHASE1","title":"Vyxeos® With Clofarabine for Pediatric AML","status":"RECRUITING","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2020-11-06","conditions":"Relapsed Pediatric AML, Refractory Pediatric AML","enrollment":25},{"nctId":"NCT00932412","phase":"PHASE2","title":"The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-03","conditions":"Acute Myeloid Leukemia","enrollment":735},{"nctId":"NCT02085408","phase":"PHASE3","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-04","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","enrollment":727},{"nctId":"NCT01228331","phase":"PHASE2, PHASE3","title":"Clofarabine or High-Dose Cytarabine and Pegaspargase in Children with ALL","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2010-10","conditions":"Leukemia","enrollment":745},{"nctId":"NCT02135874","phase":"PHASE2","title":"Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-27","conditions":"Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Leukemia of Ambiguous Lineage","enrollment":16},{"nctId":"NCT02013167","phase":"PHASE3","title":"Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)","status":"TERMINATED","sponsor":"Amgen","startDate":"2014-01-03","conditions":"Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia","enrollment":405},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT00503880","phase":"PHASE1, PHASE2","title":"Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2007-05-07","conditions":"Myelodysplastic Syndromes","enrollment":2},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT01842672","phase":"PHASE1, PHASE2","title":"Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2013-03","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoblastic Lymphoma","enrollment":41},{"nctId":"NCT02686593","phase":"PHASE2","title":"Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-02-01","conditions":"Acute Myeloid Leukemia","enrollment":50},{"nctId":"NCT01700946","phase":"PHASE2","title":"Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-04-15","conditions":"Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood B-Lymphoblastic Lymphoma","enrollment":80},{"nctId":"NCT00549848","phase":"PHASE3","title":"Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-10-29","conditions":"Acute Lymphoblastic Leukemia","enrollment":600},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT01451515","phase":"PHASE2","title":"NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-05-25","conditions":"Lymphoblastic Lymphoma","enrollment":23},{"nctId":"NCT01158885","phase":"PHASE2","title":"Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2010-08","conditions":"Minimal Residual Disease, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute","enrollment":2},{"nctId":"NCT00703820","phase":"PHASE3","title":"Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2008-08-04","conditions":"Acute Myeloid Leukemia","enrollment":324},{"nctId":"NCT00067028","phase":"PHASE2","title":"Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-12","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia","enrollment":116},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT01289457","phase":"PHASE1, PHASE2","title":"Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-02-02","conditions":"Leukemia","enrollment":282},{"nctId":"NCT00939653","phase":"PHASE2","title":"T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)","status":"TERMINATED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2009-07-10","conditions":"Relapsed Acute Myelogenous Leukemia","enrollment":6},{"nctId":"NCT01794702","phase":"PHASE1, PHASE2","title":"Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-20","conditions":"Leukemia","enrollment":65},{"nctId":"NCT02518750","phase":"PHASE2","title":"Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2016-11-23","conditions":"Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell","enrollment":3},{"nctId":"NCT01031368","phase":"PHASE1","title":"Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Nohla Therapeutics, Inc.","startDate":"2009-12","conditions":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)","enrollment":29},{"nctId":"NCT00065143","phase":"PHASE2","title":"Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2003-06-23","conditions":"Leukemia, Myeloid, Myelodysplastic Syndromes","enrollment":60},{"nctId":"NCT01025154","phase":"PHASE2","title":"Clofarabine, Idarubicin, and Cytarabine Combination in Acute Myeloid Leukemia (AML) Induction","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-01","conditions":"Acute Myeloid Leukemia","enrollment":63},{"nctId":"NCT00295841","phase":"PHASE1","title":"Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-02","conditions":"Leukemia","enrollment":53},{"nctId":"NCT01444742","phase":"PHASE2","title":"Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-11-16","conditions":"Leukemia, Myeloproliferative Diseases","enrollment":81},{"nctId":"NCT00602225","phase":"PHASE1, PHASE2","title":"Clofarabine, Cytarabine, and G-CSF in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2007-12","conditions":"Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":50},{"nctId":"NCT00908167","phase":"PHASE1","title":"Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2009-09","conditions":"Acute Myeloid Leukemia, Infantile Leukemia (Both AML and ALL), Myelodysplastic Syndrome","enrollment":44},{"nctId":"NCT00945815","phase":"PHASE2","title":"S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2010-09","conditions":"Leukemia","enrollment":35},{"nctId":"NCT01101880","phase":"PHASE2","title":"Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-08","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":50},{"nctId":"NCT00839982","phase":"PHASE1, PHASE2","title":"Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-11","conditions":"Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":35},{"nctId":"NCT01656031","phase":"PHASE2","title":"A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2005-02","conditions":"Leukemia","enrollment":39},{"nctId":"NCT00372619","phase":"PHASE1, PHASE2","title":"Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2007-03","conditions":"Leukemia","enrollment":74},{"nctId":"NCT00863434","phase":"PHASE2","title":"Clofarabine and Cytarabine in Treating Patients With Acute Myeloid Leukemia With Minimal Residual Disease","status":"TERMINATED","sponsor":"University of Washington","startDate":"2009-02","conditions":"Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","enrollment":2},{"nctId":"NCT00973752","phase":"PHASE2","title":"Treatment of Older Adults With Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-08","conditions":"Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT01621477","phase":"PHASE2","title":"T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant","status":"TERMINATED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-08","conditions":"Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia","enrollment":34},{"nctId":"NCT02844530","phase":"PHASE2","title":"Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL","status":"WITHDRAWN","sponsor":"Nantes University Hospital","startDate":"","conditions":"CD22+ Relapsed/Refractory B-ALL","enrollment":""},{"nctId":"NCT01960387","phase":"PHASE2","title":"Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"University of Pittsburgh","startDate":"2013-10","conditions":"Acute Myeloid Leukemia","enrollment":2},{"nctId":"NCT00778375","phase":"PHASE2","title":"Clofarabine Plus Low-Dose Cytarabine Induction and Decitabine Consolidation in Frontline Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-10","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":122},{"nctId":"NCT00529360","phase":"PHASE1, PHASE2","title":"Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL","status":"COMPLETED","sponsor":"New York Medical College","startDate":"2007-06","conditions":"Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia","enrollment":32},{"nctId":"NCT01295307","phase":"PHASE2","title":"Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Technische Universität Dresden","startDate":"2011-03","conditions":"Acute Myeloid Leukemia","enrollment":86},{"nctId":"NCT00337168","phase":"PHASE2","title":"S0530 Cytarabine and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2006-10","conditions":"Leukemia","enrollment":36},{"nctId":"NCT01188174","phase":"PHASE2","title":"Clofarabine/Ara-C Treatment Combined With Reduced-intensity Conditioning Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Primary Treatment Failure","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2010-07","conditions":"AML","enrollment":26},{"nctId":"NCT00593645","phase":"PHASE2","title":"Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2007-11","conditions":"Myelodysplastic Syndromes, Acute Myeloid Leukemia","enrollment":7},{"nctId":"NCT01236144","phase":"PHASE1, PHASE2","title":"A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome.","status":"COMPLETED","sponsor":"Cardiff University","startDate":"2011-04","conditions":"Acute Myeloid Leukaemia, High Risk Myelodysplastic Syndrome","enrollment":113},{"nctId":"NCT00317642","phase":"PHASE3","title":"A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2006-08","conditions":"Acute Myelogenous Leukemia","enrollment":326},{"nctId":"NCT01193400","phase":"PHASE2","title":"Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equal to 60 Years","status":"TERMINATED","sponsor":"PETHEMA Foundation","startDate":"2010-09","conditions":"Acute Myelogenous Leukemia","enrollment":75},{"nctId":"NCT01500161","phase":"PHASE2","title":"Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match","status":"TERMINATED","sponsor":"Texas Oncology Cancer Center","startDate":"2011-11","conditions":"Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia","enrollment":1},{"nctId":"NCT01302106","phase":"PHASE2","title":"Study of Clofarabine in Combination With Low Dose Cytarabine to Treat Myelodysplastic Syndromes","status":"WITHDRAWN","sponsor":"Fondazione Italiana Sindromi Mielodisplastiche-ETS","startDate":"","conditions":"Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT00454480","phase":"PHASE2, PHASE3","title":"Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"The University of New South Wales","startDate":"2006-08","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":2000},{"nctId":"NCT00334074","phase":"PHASE2","title":"Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS","status":"COMPLETED","sponsor":"Baylor Research Institute","startDate":"2005-08","conditions":"Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia","enrollment":30},{"nctId":"NCT00088218","phase":"PHASE2","title":"Clofarabine vs Clofarabine in Plus With Low-Dose Ara-C in Previously Untreated Patients With Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS).","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":95},{"nctId":"NCT00838240","phase":"PHASE1, PHASE2","title":"Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2008-11","conditions":"Leukemia, Myelodysplastic Syndromes","enrollment":114},{"nctId":"NCT00081822","phase":"PHASE1","title":"Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2004-01","conditions":"Acute Myeloid Leukemia","enrollment":23},{"nctId":"NCT01534702","phase":"PHASE1, PHASE2","title":"Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"2012-01","conditions":"Acute Myeloid Leukemia","enrollment":60},{"nctId":"NCT01423175","phase":"PHASE2","title":"ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"2011-07","conditions":"Acute Myeloid Leukemia, MDS","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Clofarabine, ara-C","genericName":"Clofarabine, ara-C","companyName":"Hannover Medical School","companyId":"hannover-medical-school","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clofarabine is a chemotherapy medication used to treat various types of leukemia and lymphoma, including CD22+ Relapsed/Refractory B-ALL, Acute Myeloid Leukemia, and Acute Lymphoblastic Leukemia. It is often used in combination with other treatments, such as immunotherapy and chemotherapy, as part of clinical trials to evaluate its efficacy in these conditions.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}